Leeward Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Leeward Financial Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-716	Closed	-$280K	–	104
2025 Q3	$280K	Hold	716	–	–	0.08%	90
2025 Q2	$319K	Buy	716 +58	+9%	+$26.7K	0.1%	80
2025 Q1	$319K	Sell	658 -357	-35%	-$166K	0.12%	68
2024 Q4	$409K	Sell	1,015 -997	-50%	-$462K	0.15%	63
2024 Q3	$936K	Buy	2,012 +5	+0.2%	+$2.4K	0.35%	57
2024 Q2	$941K	Sell	2,007 -6,679	-77%	-$2.9M	0.38%	54
2024 Q1	$3.63M	Buy	8,686 +127	+1%	+$53.7K	1.54%	23
2023 Q4	$3.48M	Sell	8,559 -343	-4%	-$127K	1.68%	20
2023 Q3	$3.1M	Buy	8,902 +1,375	+18%	+$481K	1.71%	17
2023 Q2	$2.65M	Buy	+7,527	New	+$2.54M	1.52%	19

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Leeward Financial Partners's VRTX Position: Q4 2025 in Review

Leeward Financial Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 716 shares — an estimated $280K sold.

Leeward Financial Partners first reported a position in VRTX in Q2 2023 and held it in 10 quarters. The position peaked at $3.63M in Q1 2024. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Leeward Financial Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Leeward Financial Partners sold 716 Vertex Pharmaceuticals shares in Q4 2025, an estimated $280K.
Leeward Financial Partners first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 10 quarters.
Leeward Financial Partners's Vertex Pharmaceuticals position peaked at $3.63M in Q1 2024.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Leeward Financial Partners's 13F filing for Q4 2025, filed 9 Feb 2026.